Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: A randomised controlled trial

Lancet

Volumn 353, Issue 9168, 1999, Pages 1923-1929

  Levy, Y ^a   Capitant, C ^b   Houhou, S ^a   Carriere, I ^b   Viard, J P ^c   Goujard, C ^c   Gastaut, J A ^c   Oksenhendler, E ^c   Boumsell, L ^c   Gomard, E ^c   Rabian, C ^c   Weiss, L ^c   Guillet, J G ^c   Delfraissy, J F ^c   Aboulker, J P ^b   Seligmann, M ^c  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM   (France)

^c ANRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD28 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; DIDANOSINE; INTERLEUKIN 2; MITOGENIC AGENT; ZIDOVUDINE;

ADULT; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FACE EDEMA; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LARYNX EDEMA; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE; VIRUS LOAD; VOMITING;

EID: 0033526641     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)07345-0     Document Type: Article

References (24)

1. Pantaleo G, Fauci AS. New concepts in the immunopathogenesis of HIV infection. Annu Rev Immunol 1995; 13: 487-512.
2. Perelson AS, Essunger P, Cao YZ, et al. Decay characteristics of HIV-infected compartments during combination therapy. Nature 1997; 387: 188-91.
3. Kelleher AD, Carr A, Zauders J, Cooper DA. Alterations in the immune response of human immunodeficiency virus HIV-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996; 173: 321-29.
4. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostatis and function in advanced HIV disease. Science 1997; 277: 112-16.
5. Connors M, Kovacs JA, Krevat S, et al. HIV infection indices changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral ot immune-based therapies. Nat Med 1997; 3: 533-40.
6. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral load reduction after highly active antiretroviral therapy in advanced HIV disease. Lancet 1998; 351: 1682-86.
7. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988; 240: 1169-76.
8. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection: a preliminary study. N Engl J Med 1995; 332: 567-75.
9. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of Interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996; 335: 1350-56.
10. Teppler H, Kaplan G, Smith KA, Montana AL, Meyn P, Cohn ZA. Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin-2 in patients with human immunodeficiency virus type 1 infection. J Exp Med 1993; 177: 483-92.
11. Teppler H, Kaplan G, Smith KA, et al. Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection. J Infect Dis 1993; 167: 291-98.
12. Davey RT, Chaitt DG, Piscitelli SC, et al. Subcutaneous administration of interleukin-2 in human deficiency virus type 1-infected persons. J Infect Dis 1997; 175: 781-89.
13. Schiavon V, Roth P, Bolton WE, Farcet JP, Bensussan A, Boumsell L. Lymphocytes subsets in normal individuals: analysis by four color immunofluorescence and flow cytometry on whole blood. Tissue Antigens 1996; 48: 312-18.
14. Dalod M, Fiorentino S, Delamare C, et al. Delayed virus specific CD8+ cytotoxic T lymphocyte activity in an HIV-infected individual with high CD4+ cell count: correlations with various parameters of disease progression. AIDS Res Hum Retrovir 1996; 12: 497-506.
15. Dalod M, Harzic M, Pellegrin I, et al. Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with systomatic primary infection receiving antiretroviral triple therapy. J Infect Dis 1998; 178: 61-69.
16. Delta Coordinataing committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine aone in HIV-infected individuals. Lancet 1996; 348: 238-91.
17. Wood R, Montoya JG, Kundu SK, Schwartz DH, Merigan TC. Safety and efficacy of polyethylene glycol-modified interleukin-2 and Zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study. J Infect Dis 1993; 167: 519-525.
18. Carr A, Emery S, Lloyd A, et al. Outpatients continuous intravenous interleukin-2 or subcutaneous polyethylene glycol modified IL-2 in human immunodeficiency virus-infected patients: a randomised, controlled, multicentre study. J Infect Dis 1998; 187: 992-99.
19. De Paoli P, Zanussi S, Simonelli C, et al. Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects. J Clin Invest 1997; 100: 2737-43.
20. Vanham G, Kestens L, De Meester I, et al. Decrease expression of the memory marker CD26 on both CD4+ and CD8+ lymphocytes of HIV-infected subjects. J Acquire Immun Defic Syndr 1993; 6: 749-57.
21. Borthwick NJ, Bofill M, Gombert WM, et al. Lymphocyte activation in HIV infection: II functional defects of CD28-T cells. AIDS 1994; 8: 431-41.
22. Brinchmann JE, Dobloug JH, Heger BH, Haaheim LL, Sannes M, Egeland I. Expression of costimulatory molecule CD28 on T cells in human immunodeficiency virus type 1 infection: functional and clinical correlation. J Infect Dis 1994; 169: 730-38.
23. Rosenberg ES, Bllingsley JM, Caliendo AM, Vigorous HIV-1 specific CD4+ T cell response associated with control of viremia. Science 1997; 278: 1447-50.
24. Barker E, Bossart KN, Fujimura SH, Levy JA. CD28 constimulation increases CD8+ cell suppression of HIV replication. J Immunol 1997; 159: 5123-31.